Schrodinger Inc (SDGR NASDAQ) stock market data APIs
$21.3675
0.97(4.5%)
as of July 18, 2025
Try our APIs with
free plan!
Schrodinger Inc Financial Data Overview
Price chart is built with
Anychart
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Prev. Close
21.3675
Open
22.3414
High
22.5322
Low
21.3488
52 wk Range
16.602-28.47
Market Cap
1 589 M
Shares Outstanding
64 213 K
Revenue
230 M
EPS
-0.64
Beta
1.621
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Schrodinger Inc data using free add-ons & libraries
Get Schrodinger Inc Fundamental Data
Schrodinger Inc Fundamental data includes:
- Net Revenue: 230 M
- EBITDA: -186 440 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-29
- EPS/Forecast: -0.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Schrodinger Inc News
New
Schrodinger stock maintains Buy rating at Citi on Ajax collaboration
Investing.com - Citi has reiterated a Buy rating and $39.00 price target on Schrodinger (NASDAQ:SDGR) following the company’s announcement of an expanded research collaboration with Ajax Therapeutic...
Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration
NEW YORK/CAMBRIDGE - Ajax Therapeutics, Inc. and Schrödinger, Inc. (NASDAQ:SDGR), a $1.56 billion market cap biotech company with robust revenue growth of 22% over the last twelve months, announced T...
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target
NEW YORK & CAMBRIDGE, Mass., July 17, 2025--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to inc...
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
